A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody

Primary Objective of the study:

（1）To evaluate the safety, tolerability, and Rabies Virus Neutralizing Activity (RVNA) of different doses of a recombinant human anti-rabies virus monoclonal antibody injection (referred to as the anti-rabies mAb), administered alone or in combination with a human rabies vaccine, compared to human rabies immune globulin, in healthy adult participants aged 18-60.

Secondary Objective of the study:

1. To evaluate the pharmacokinetics (PK) of the anti-rabies mAb administered alone or in combination with a human rabies vaccine in healthy adult participants aged 18-60. 2. To evaluate the incidence of anti-drug antibodies for the anti-rabies mAb compared to human rabies immune globulin, administered alone or in combination with a human rabies vaccine, in healthy adult participants aged 18-60. 3. To provide a basis for dose selection for Phase III clinical studies.